首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the National Cooperative Growth Study experience.
【24h】

Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the National Cooperative Growth Study experience.

机译:使用生物合成生长激素治疗的生长激素缺乏症儿童的成人身高:国家合作生长研究的经验。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To determine whether the height gain during puberty in children with growth hormone deficiency (GHD) who are treated with biosynthetic growth hormone (GH) is similar to that in otherwise healthy children with delayed bone ages and whether the height standard deviation score (SDS), which began to increase before puberty, continues to increase during puberty. METHODS: The inclusion criteria included a diagnosis of idiopathic GHD, prepubertal on enrollment in the National Cooperative Growth Study, and spontaneous onset of puberty, as defined by Tanner stage 2 breast development in girls and a testicular volume of at least 3 mL in boys. Near-adult height was judged to have been attained in the subjects who had reached a chronologic age of at least 18 years (females) or 20 years (males) or had reached at least pubertal stage 4 and a chronologic age of at least 14 years (females) or 16 years (males). These subjects constituted group 1. Group 2 was a subgroup of these subjects who met a more stringent criterion for near-adult height; in addition to meeting the above criteria, they had to have attained a bone age of at least 14 years (females) or 16 years (males). RESULTS: Group 1 consisted of 480 males and 194 females. Group 2 consisted of 153 males and 105 females. In the subjects in group 1, the Tanner pubertal stage 2 was 14.1 +/- 1.5 years in males and 12.6 +/- 1.6 years in females; the bone age at this stage was 11. 9 +/- 1.5 years in males and 10.6 +/- 1.5 years in females; and the height SDS was -2.1 +/- 0.9 in males and -2.4 +/- 0.9 in females. The total height gained during puberty was 22.4 +/- 7.9 cm in males and 17.4 +/- 6.3 cm in females; the percentage of adult height gained during puberty was 13.3% +/- 4.6% in males and 11.3% +/- 4.0% in females; the near-adult height SDS was -1.3 +/- 1.0 in males and -1.6 +/- 0.9 in females; and the target adult height SDS was -0.4 +/- 0.8 in males and -0.5 +/- 0.7 in females. The growth characteristics in the subjects in group 2 were of similar magnitude. In both groups, there was a significant negative correlation between age at the onset of Tanner stage 2 and both the total height gained during puberty and the percentage of adult height gained. CONCLUSIONS: The growth characteristics of these subjects were similar to those reported in normal children and in previous reports of the pubertal growth in smaller populations of children with GHD. The height SDS increased in these subjects during puberty, but the target adult height SDS was not attained. This is a strong argument for early diagnosis and treatment in children with GHD to optimize prepubertal growth.
机译:目的:确定接受生物合成生长激素(GH)治疗的生长激素缺乏症(GHD)儿童在青春期的身高增长是否与其他健康的骨龄延迟儿童相似,以及身高标准差得分(SDS) )(在青春期之前开始增加),而在青春期后继续增加。方法:纳入标准包括诊断为特发性GHD,参加国家合作生长研究的青春期前,以及女孩的Tanner 2期乳房发育和男孩的睾丸体积至少3 mL所定义的青春期自发性发作。年龄已达到至少18岁(女性)或20岁(男性)或至少达到青春期4且年龄至少14岁的受试者被判定为接近成人身高(女性)或16岁(男性)。这些受试者构成第1组。第2组是这些受试者的一个亚组,它们满足更严格的接近成人身高标准;除了满足上述标准外,他们还必须达到至少14岁(女性)或16岁(男性)的骨龄。结果:第一组由480名男性和194名女性组成。第2组由153名男性和105名女性组成。在第1组的受试者中,男性的Tanner青春期阶段2为14.1 +/- 1.5岁,女性为12.6 +/- 1.6岁。此阶段的骨龄男性为11. 9 +/- 1.5岁,女性为10.6 +/- 1.5岁;男性的高度SDS为-2.1 +/- 0.9,女性为-2.4 +/- 0.9。男性在青春期获得的总身高为22.4 +/- 7.9厘米,女性为17.4 +/- 6.3厘米;男性在青春期期间获得的成年人身高百分比为13.3%+/- 4.6%,女性为11.3%+/- 4.0%;男性的近成人身高SDS为-1.3 +/- 1.0,女性为-1.6 +/- 0.9;男性的成人目标身高SDS为-0.4 +/- 0.8,女性为-0.5 +/- 0.7。第2组受试者的生长特征具有相似的大小。在两组中,坦纳(Tanner)2期发病年龄与青春期获得的总身高和成年身高的百分比之间均存在显着的负相关。结论:这些受试者的生长特征与正常儿童和以前的报告有关,GHD儿童较小人群的青春期生长相似。这些对象的身高SDS在青春期期间增加,但未达到成人的目标身高SDS。这是对GHD儿童进行早期诊断和治疗以优化青春期前生长的有力论据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号